#USA #Denver #Alzheimer's #Cerecin #NIHR HealthTech

Cerecin Joins NIHR HealthTech Research Centre as an Industry Partner

Cerecin, a leading biotech firm specializing in neurometabolism, has entered into an exciting partnership with the NIHR HealthTech Research Centre focused on Brain Health. This centers around a unified mission to tackle dementia through innovative technologies and research.

The NIHR HealthTech Research Centre, based at King's College London and affiliated with the South London and Maudsley NHS Foundation Trust, encompasses prominent entities including GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations. Their collective goal is to pioneer advancements in the diagnosis, treatment, and care surrounding dementia, significantly mitigating its societal burden.

Under the direction of Professor Dag Aarsland, who leads the Centre for Healthy Brain Ageing at the Institute of Psychiatry, Psychology and Neuroscience, alongside Professor Clive Ballard from the University of Exeter, this initiative synthesizes exceptional academic knowledge with industry ingenuity. This collaboration aims to throw light on one of neuroscience's most pressing issues.

Dr. Charles Stacey, President and CEO of Cerecin, expressed enthusiasm about this new partnership, emphasizing the importance of collaboration between academia and industry to fast-track impactful innovation. He stated, "We are thrilled to become an industry partner with the HRC at King's College London, a renowned hub for neuroscience research. Our collaborative efforts will help expedite breakthroughs that lead to tangible solutions in the market."

Dr. Richard Siow, Director of Ageing Research at King's (ARK) and Industry Lead for the NIHR HealthTech Research Centre, extended a warm welcome to Cerecin as their new partner, recognizing the company's pivotal role in neurometabolism. Dr. Siow noted, "Cerecin stands at the forefront of essential neuroscience research that promises significant benefits for healthy brain ageing. We eagerly await exploring collaborative prospects concerning Cerecin's pipeline and beyond."

As Cerecin progresses with its ALTER AD study—its vital Phase 3 program targeting Alzheimer's disease dementia—this partnership will enhance its strategic footing as a prominent player in neurology. By collaborating with independent innovators and other industry leaders, Cerecin aims to enrich its portfolio while setting new industry standards.

About Cerecin

Cerecin is a clinical-stage biotechnology firm based in the United States, focused on drug development that targets the metabolic foundations of neurological disorders. With extensive experience in neurology drug development coupled with lipid science, the company aspires to rise as a global leader in neurology therapeutics. Its flagship compound, tricaprilin, is presently in Phase 3 of the ALTER AD study for mild to moderate Alzheimer's dementia. This innovative compound boosts ketone production by sending medium-chain fatty acids directly to hepatic mitochondria for rapid metabolism to acetyl-CoA.

This pivotal mechanism sidesteps sugar metabolism impairment while facilitating energy generation in malfunctioning cells, thereby addressing an essential unmet need in Alzheimer's treatment. Cerecin’s partnerships with multinational companies such as Nestlé, Wilmar, and IOI reinforce its endeavors to innovate continuously in neurometabolic therapy.

For further insights about Cerecin’s innovations and developments, visit their website at www.cerecin.com or connect with them on LinkedIn.